University Staff Directory The University of Adelaide Australia
Faculties & Divisions | People A to Z | Media Expertise | Phonebook
Public browsing [Login]
Text Zoom: S | M | L

Dr Mohammed Alsharifi

Telephone +61 8 8313 4632
Position Researh Fellow
Email mohammed.alsharifi@adelaide.edu.au
Fax +61 8 8313 4362
Building Molecular Life Sciences
Floor/Room 5 18
Campus North Terrace
Org Unit School of Molecular and Biomedical Science

To link to this page, please use the following URL:
http://www.adelaide.edu.au/directory/mohammed.alsharifi

Biography/ Background

Dr Alsharifi grew up in Babylon/Iraq and studied Veterinary Medicine at Baghdad University. He was increasingly interested in medical research and after coming to Australia he studied Biomedical Science at Monash University. He then moved to the Australian National University to take up a PhD scholarship at The John Curtin School of Medical Research, and investigated with Arno Müllbacher, Robert Blanden, and Mario Lobigs the immunobiology of an alphavirus infection. During his early years in research he discovered a period of exhaustion in type-I interferon response following an acute viral infection, which may explain the clinically known observation that virus-infected patients are at increased risk to a more sever secondary viral and/or bacterial infection. Following the completion of his PhD studies, he investigated with Prof Müllbacher the possibility of using gamma-irradiated influenza virus as a universal flu vaccine. In 2008, he was awarded the Hanson Fellowship to continue his research into the universal Flu vaccine and also to investigate the possibility of producing other viral vaccines using similar technique to that used for influenza. His flu vaccine research has been featured in the Catalyst program on ABC (http://www.abc.net.au/catalyst/stories/2613604.htm), and in many newspaper articles such as (http://www.news.com.au/adelaidenow/story/0,,25625291-5018662,00.html) and  (http://www.news.com.au/adelaidenow/story/0,22606,25406694-5006301,00.html).

Research Interests

Opportunities for Honours and PhD students:

I. Cross-Protective influenza vaccine.

Protection against re-infection with homotypic influenza virus is mediated primarily by neutralizing antibodies but recovery from newly arisen influenza virus infections requires cytotoxic CD8+ T (Tc) cells. While neutralizing antibodies target mainly the viral surface glycoproteins (HA and NA), which are subject to frequent antigenic variation, influenza-immune Tc cells target the more conserved proteins, such as the viral nucleoprotein (NP) and matrix protein. Accordingly, any universal influenza vaccine should have the capability of inducing cross-protective Tc cell responses. We have reported that gamma-irradiated influenza A virus preparations can induce cross-reactive Tc cell responses and shown that a single intranasal administration of g-H1N1 protects mice against lethal avian H5N1 and other heterotypic influenza A infections. potential projects for postgraduate research students would be in the areas of:

1.      Cross-protective cytotoxic T cell responses induced by g-flu.

2.      The role of the cytolytic effector molecules in recovery from influenza infection.

3.      Cross-protective antibody responses induced by g-flu.

4.      Recognition of g-flu and the induction of cross-protective immunity.

 

 II. Exhaustion of IFN-I response and the susceptibility to secondary infections.

We have previously reported that type I interferon (IFN-I) response mediates systemic, partial lymphocyte activation which is evident by elevated expression of CD69 and CD86. Using avirulent strain of Semliki Forest Virus (SFV) as a model, we have found that induction of both IFN-I response and the associated lymphocyte activation to be dependent on virus viability as γ-irradiated SFV (γ-SFV) failed to induce either. We have also reported a period of exhausted IFN-I responses as a result of primary viral infections, which was associated with enhanced susceptibility to a secondary infection with an unrelated virus. Our aim is to investigate the underlying factors responsible for the deficiency in IFN-I responses following acute viral infections, and to address some therapeutic approaches to alleviate the period of the enhanced susceptibility. Interestingly, we found γ-irradiation of influenza virus, in contrast to that of SFV, did not abrogate the induction of IFN-I. Thus, IFN-I responses of two unrelated ssRNA viruses and their γ-irradiated counterparts will be investigated to establish a model to study the underlying factors responsible for the deficiency in IFN-I responses. potential projects for postgraduate research students would be in the areas of:

1.      Induction of IFN-I responses by SFV and Flu and their g-irradiated counterparts.

2.      The consequences of the sub-optimal response to secondary viral infections.

3.      The underlying factors for the deficient IFN-I response following an acute viral infection.

4.      Possible therapeutic approaches to alleviate the enhanced susceptibility to secondary infections.

 

Publications

1. Mohammed Alsharifi, Mario Lobigs, Matthias Regner, Eva Lee, Aulikki Koskinen, Arno Müllbacher. Type-I interferons, in response to viral infection, trigger systemic, partial, lymphocyte activation. The Journal of Immunology, 2005; 175: 4635-4640.

 

2. David B. Rosen, Jayaram Bettadapura, Mohammed Alsharifi, Porunelloor A. Mathew, Hilary S. Warren, and Lewis L. Lanier. CUTTING EDGE: Lectin-like transcript-1 (LLT1) is a ligand for the inhibitory human NKR-P1A receptor. The Journal of Immunology, 2005; 176:7796-7799.

 

3. Mohammed Alsharifi, Mario Lobigs, Markus M. Simon, Astrid Kersten, Klaus Müller, Aulikki Koskinen, Eva Lee and Arno Müllbacher. NK cells mediated immunopathology during an acute viral infection of the CNS. The European Journal of Immunology, 2006; 36:887-96.

 

4. Arno Müllbacher, Mario Lobigs, Mohammed Alsharifi and Matthias Regner. A new look at cytotoxic T cell immunity as target for an influenza vaccine is warranted. The Lancet Infectious Diseases, 2006; 6: 255-256. 

 

5. Mohammed Alsharifi, Mario Lobigs, Robert Blanden, Matthias Regner, Eva Lee, Aulikki Koskinen, Arno Müllbacher. Exhaustion of type-I Interferon following an acute viral infection. The Journal of Immunology, 2006; 177: 3235–3241.

 

6. Alison Budd, Lisa Alleva, Mohammed Alsharifi, Aulikki Koskinen, Victoria Smyth, Arno Müllbacher, Jeff Wood, Ian Clark. Increased Survival after Gemfibrozil Treatment of Severe Murine Influenza. Antimicrobial Agents and Chemotherapy, 2007; 51:2965-2968.

 

7. Mohammed Alsharifi, Arno Müllbacher, Matthias Regner. Interferon Type-I responses in Primary and Secondary Infections. Immunology and Cell Biology, 2008; 86: 239-245.

 

8. Mohammed Alsharifi, Mario Lobigs, Jayaram Bettadapura, Aulikki Koskinen, Arno Müllbacher. Restrict alphavirus replication in perforin and Fas-L double deficient mice. Journal of General Virology, 2008; 89:1942-1944.

 

9. Mario Lobigs, Maximilian Larena, Mohammed Alsharifi, Eva Lee and Megan Pavy. Live chimeric and inactivated Japanese encephalitis virus vaccines differ in their cross-protective value against Murray Valley encephalitis virus. Journal of Virology. 2009;83(6):2436-45. Epub 2008 Dec 24.

 

10. Mohammed Alsharifi, Yoichi Furuya, Timothy R. Bowden, Mario Lobigs, Aulikki Koskinen, Matthias Regner, Lee Trinidad, David B. Boyle and Arno Müllbacher. Intranasal flu vaccine protective against seasonal and H5N1 avian influenza infections. PLoS ONE. 2009;4(4):e5336. Epub 2009 Apr 29.

 

 

Entry last updated: Wednesday, 29 Jan 2014

The information in this directory is provided to support the academic, administrative and business activities of the University of Adelaide. To facilitate these activities, entries in the University Phone Directory are not limited to University employees. The use of information provided here for any other purpose, including the sending of unsolicited commercial material via email or any other electronic format, is strictly prohibited. The University reserves the right to recover all costs incurred in the event of breach of this policy.